Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 159

Similar articles for PubMed (Select 19521678)

1.

Altered reward functions in patients on atypical antipsychotic medication in line with the revised dopamine hypothesis of schizophrenia.

Walter H, Kammerer H, Frasch K, Spitzer M, Abler B.

Psychopharmacology (Berl). 2009 Sep;206(1):121-32. doi: 10.1007/s00213-009-1586-4. Epub 2009 Jun 12.

PMID:
19521678
2.

Alterations of the brain reward system in antipsychotic naïve schizophrenia patients.

Nielsen MØ, Rostrup E, Wulff S, Bak N, Lublin H, Kapur S, Glenthøj B.

Biol Psychiatry. 2012 May 15;71(10):898-905. doi: 10.1016/j.biopsych.2012.02.007. Epub 2012 Mar 13.

PMID:
22418013
3.

Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics.

Juckel G, Schlagenhauf F, Koslowski M, Filonov D, Wüstenberg T, Villringer A, Knutson B, Kienast T, Gallinat J, Wrase J, Heinz A.

Psychopharmacology (Berl). 2006 Aug;187(2):222-8. Epub 2006 May 24.

PMID:
16721614
4.
5.
6.

Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine.

Schlagenhauf F, Juckel G, Koslowski M, Kahnt T, Knutson B, Dembler T, Kienast T, Gallinat J, Wrase J, Heinz A.

Psychopharmacology (Berl). 2008 Mar;196(4):673-84. Epub 2007 Dec 21.

PMID:
18097655
7.

The influence of antipsychotic treatment on brain reward system reactivity in schizophrenia patients.

Kirsch P, Ronshausen S, Mier D, Gallhofer B.

Pharmacopsychiatry. 2007 Sep;40(5):196-8.

PMID:
17874350
8.

Dopaminergic modulation of the reward system in schizophrenia: a placebo-controlled dopamine depletion fMRI study.

da Silva Alves F, Bakker G, Schmitz N, Abeling N, Hasler G, van der Meer J, Nederveen A, de Haan L, Linszen D, van Amelsvoort T.

Eur Neuropsychopharmacol. 2013 Nov;23(11):1577-86. doi: 10.1016/j.euroneuro.2013.06.008. Epub 2013 Aug 24.

9.

Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia.

Bertolino A, Caforio G, Blasi G, De Candia M, Latorre V, Petruzzella V, Altamura M, Nappi G, Papa S, Callicott JH, Mattay VS, Bellomo A, Scarabino T, Weinberger DR, Nardini M.

Am J Psychiatry. 2004 Oct;161(10):1798-805.

PMID:
15465976
10.

Pavlovian reward prediction and receipt in schizophrenia: relationship to anhedonia.

Dowd EC, Barch DM.

PLoS One. 2012;7(5):e35622. doi: 10.1371/journal.pone.0035622. Epub 2012 May 4.

11.

Altered effect of dopamine transporter 3'UTR VNTR genotype on prefrontal and striatal function in schizophrenia.

Prata DP, Mechelli A, Picchioni MM, Fu CH, Toulopoulou T, Bramon E, Walshe M, Murray RM, Collier DA, McGuire P.

Arch Gen Psychiatry. 2009 Nov;66(11):1162-72. doi: 10.1001/archgenpsychiatry.2009.147.

PMID:
19884604
12.

[Cognition, schizophrenia and the effect of antipsychotics].

Stip E.

Encephale. 2006 May-Jun;32(3 Pt 1):341-50. Review. French.

PMID:
16840928
13.

Effects of treatment with the atypical neuroleptic quetiapine on working memory function: a functional MRI follow-up investigation.

Meisenzahl EM, Scheuerecker J, Zipse M, Ufer S, Wiesmann M, Frodl T, Koutsouleris N, Zetzsche T, Schmitt G, Riedel M, Spellmann I, Dehning S, Linn J, Brückmann H, Möller HJ.

Eur Arch Psychiatry Clin Neurosci. 2006 Dec;256(8):522-31. Epub 2006 Dec 6.

PMID:
17151834
14.

Striatal response to reward anticipation: evidence for a systems-level intermediate phenotype for schizophrenia.

Grimm O, Heinz A, Walter H, Kirsch P, Erk S, Haddad L, Plichta MM, Romanczuk-Seiferth N, Pöhland L, Mohnke S, Mühleisen TW, Mattheisen M, Witt SH, Schäfer A, Cichon S, Nöthen M, Rietschel M, Tost H, Meyer-Lindenberg A.

JAMA Psychiatry. 2014 May;71(5):531-9. doi: 10.1001/jamapsychiatry.2014.9.

PMID:
24622944
15.

Ventral striatal activation during attribution of stimulus saliency and reward anticipation is correlated in unmedicated first episode schizophrenia patients.

Esslinger C, Englisch S, Inta D, Rausch F, Schirmbeck F, Mier D, Kirsch P, Meyer-Lindenberg A, Zink M.

Schizophr Res. 2012 Sep;140(1-3):114-21. doi: 10.1016/j.schres.2012.06.025. Epub 2012 Jul 10.

PMID:
22784688
16.

The revised dopamine hypothesis of schizophrenia: evidence from pharmacological MRI studies with atypical antipsychotic medication.

da Silva Alves F, Figee M, van Amelsvoort T, Veltman D, de Haan L.

Psychopharmacol Bull. 2008;41(1):121-32. Review.

PMID:
18362875
17.

Ventral striatal activation during reward processing in subjects with ultra-high risk for schizophrenia.

Juckel G, Friedel E, Koslowski M, Witthaus H, Ozgürdal S, Gudlowski Y, Knutson B, Wrase J, Brüne M, Heinz A, Schlagenhauf F.

Neuropsychobiology. 2012;66(1):50-6. doi: 10.1159/000337130. Epub 2012 Jul 13.

PMID:
22797277
18.

Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia.

Bédard AM, Maheux J, Lévesque D, Samaha AN.

Schizophr Bull. 2013 May;39(3):692-702. doi: 10.1093/schbul/sbs077. Epub 2012 Aug 27.

19.

Dopaminergic dysfunction in schizophrenia: salience attribution revisited.

Heinz A, Schlagenhauf F.

Schizophr Bull. 2010 May;36(3):472-85. doi: 10.1093/schbul/sbq031. Epub 2010 May 7. Review.

20.

Schizophrenia and Parkinson's disease lead to equal motor-related changes in cortical and subcortical brain activation: an fMRI fingertapping study.

Müller JL, Deuticke C, Putzhammer A, Röder CH, Hajak G, Winkler J.

Psychiatry Clin Neurosci. 2003 Dec;57(6):562-8.

PMID:
14629703
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk